TME Pharma Enters Exclusive Talks With TMS on NOX-A12

TME Pharma signed a binding exclusive negotiation agreement and a non-binding term sheet with TMS Co. to advance NOX-A12 for glioblastoma. Resuming the Phase 2 GLORIA study is subject to a definitive deal and financing through a TMS subsidiary.